Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Diabetes is a risk factor for cancer and specifically colorectal cancer. It is also associated with increased cancer mortality. Aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 (Cox-2) inhibitors have been shown to decrease the incidence of colorectal cancer. This effect may be mediated by inhibiting prostaglandin synthesis. Long-term use of high-dose aspirin and NSAIDs is associated with significant gastrointestinal side effects. Unfortunately, the use of Cox-2 inhibitors is associated with an increased incidence of acute myocardial infarction and death from cardiovascular disease. The increased risk of cardiovascular disease in patients with diabetes results in the loss of the potential to use Cox-2 inhibitors for cancer chemoprophylaxis. Until a safer type of Cox-2 inhibitor is available, or low-dose aspirin is evaluated for chemoprophylaxis, a more intense screening programme for colorectal cancer may be appropriate for patients with diabetes, especially men. Healthcare professionals managing patients with diabetes should be aware of the increased risk of this type of cancer.
Smith
C J
CJ
Hairmyres Hospital, East Kilbride, UK. chrisjsmith@doctors.org.uk
McKay
G A
GA
Fisher
M
M
D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000191:economics / Q000209:etiology* / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D012307:Risk Factors
D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D001241:Aspirin